JP2022516651A5 - - Google Patents

Info

Publication number
JP2022516651A5
JP2022516651A5 JP2021539523A JP2021539523A JP2022516651A5 JP 2022516651 A5 JP2022516651 A5 JP 2022516651A5 JP 2021539523 A JP2021539523 A JP 2021539523A JP 2021539523 A JP2021539523 A JP 2021539523A JP 2022516651 A5 JP2022516651 A5 JP 2022516651A5
Authority
JP
Japan
Prior art keywords
disease
disorder
pyrrolo
triazole
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021539523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516651A (ja
JP7585205B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012908 external-priority patent/WO2020146615A1/en
Publication of JP2022516651A publication Critical patent/JP2022516651A/ja
Publication of JP2022516651A5 publication Critical patent/JP2022516651A5/ja
Application granted granted Critical
Publication of JP7585205B2 publication Critical patent/JP7585205B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021539523A 2019-01-11 2020-01-09 二環式ピロロトリアゾールケトン化合物及びその使用方法 Active JP7585205B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962791118P 2019-01-11 2019-01-11
US62/791,118 2019-01-11
PCT/US2020/012908 WO2020146615A1 (en) 2019-01-11 2020-01-09 Bicyclic pyrrolotriazolr ketone compounds and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022516651A JP2022516651A (ja) 2022-03-01
JP2022516651A5 true JP2022516651A5 (cg-RX-API-DMAC7.html) 2023-01-19
JP7585205B2 JP7585205B2 (ja) 2024-11-18

Family

ID=69528972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021539523A Active JP7585205B2 (ja) 2019-01-11 2020-01-09 二環式ピロロトリアゾールケトン化合物及びその使用方法

Country Status (7)

Country Link
US (2) US12344612B2 (cg-RX-API-DMAC7.html)
EP (1) EP3908586B1 (cg-RX-API-DMAC7.html)
JP (1) JP7585205B2 (cg-RX-API-DMAC7.html)
CN (1) CN113302193B (cg-RX-API-DMAC7.html)
AR (1) AR119673A1 (cg-RX-API-DMAC7.html)
TW (1) TW202043229A (cg-RX-API-DMAC7.html)
WO (1) WO2020146615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3214802A1 (en) * 2021-04-02 2022-10-06 Genentech, Inc. Processes for making bicyclic ketone compounds
WO2023225041A1 (en) 2022-05-19 2023-11-23 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1620508A1 (de) 1965-07-23 1969-09-18 Thomae Gmbh Dr K Verfahren zur Herstellung neuer 4,5,6,7-Tetrahydrothiazolo-[5,4-c]-pyridine
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3948903A (en) 1972-12-15 1976-04-06 Parke, Davis & Company Substituted N-(1,2-dihydro-2-oxonicotinyl)-cephalexins and -cephaloglycins
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
GB8610530D0 (en) 1986-04-30 1986-06-04 Fbc Ltd Herbicides
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
US6080772A (en) 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
EP1007042A4 (en) 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
JP2004502642A (ja) 2000-02-11 2004-01-29 ブリストル−マイヤーズ スクイブ カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
PL382706A1 (pl) 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
ATE410161T1 (de) 2003-05-02 2008-10-15 Elan Pharm Inc 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
EP2083009A1 (de) 2008-01-22 2009-07-29 Grünenthal GmbH Substituierte Tethrahydroimidazopyridin-Verbindungen und deren Verwendung in Arzneimitteln
CA2852964A1 (en) 2011-11-03 2013-05-10 F. Hoffmann-La Roche Ag Bicyclic piperazine compounds
JP6267193B2 (ja) 2012-05-22 2018-01-24 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 置換ジピリジルアミン類及びそれらの使用
MX2015009270A (es) 2013-01-18 2015-10-30 Hoffmann La Roche Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 (二)
TWI710558B (zh) 2013-05-01 2020-11-21 瑞士商赫孚孟拉羅股份公司 二雜芳基化合物及其用途
RU2015147601A (ru) 2013-05-01 2017-06-05 Ф. Хоффманн-Ля Рош Аг С-связанные гетероциклоалкилзамещенные пиримидины и их применения
AU2014287471C1 (en) 2013-07-10 2019-11-28 Vertex Pharmaceuticals Incorporated Fused piperidine amides as modulators of ion channels
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
CR20160418A (es) 2014-03-26 2016-11-07 Hoffmann La Roche Nuevos compuestos biciclicos de 7 eslabones
RU2017109122A (ru) 2014-08-21 2018-09-21 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы
JP6701225B2 (ja) 2015-03-09 2020-05-27 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 三環式dlk阻害剤及びその使用
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
AU2017356887B2 (en) 2016-11-08 2022-06-30 Cyclerion Therapeutics, Inc. sGC stimulators
US11071721B2 (en) 2016-12-02 2021-07-27 Genentech, Inc. Bicyclic amide compounds and methods of use thereof
US11072607B2 (en) * 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN119613408A (zh) * 2017-07-14 2025-03-14 豪夫迈·罗氏有限公司 二环酮化合物及其使用方法
WO2019072942A1 (en) 2017-10-11 2019-04-18 F. Hoffmann-La Roche Ag BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
MX2020003451A (es) 2017-10-31 2020-08-03 Hoffmann La Roche Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
JP7642098B2 (ja) カルボキシ-ベンズイミダゾールglp-1r調節化合物
JP7010935B2 (ja) Usp30の阻害剤としての活性を有するシアノ置換ヘテロ環
AU2018202148B2 (en) Substituted pyridine and pyrazine compounds as PDE4 inhibitors
JP6964576B2 (ja) 置換4−アザインドール及びglun2b受容体調節因子としてのそれらの使用
JP4814783B2 (ja) ピラゾロピリジン誘導体
JP7558334B2 (ja) PI3K-γ阻害剤としてのアミノピラジンジオール化合物
CN109071546B (zh) 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
CN105764514B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
US20210253596A1 (en) Sulfonimidamide compounds as inhibitors of interleukin-1 activity
KR102616949B1 (ko) 고리형 구조를 갖는 화합물
JP2021532124A (ja) Nlrp3インフラマソーム阻害剤
JP7029388B2 (ja) 抗がん活性を有するmdm2-p53相互作用のイソインドリノン阻害剤
JP2016523911A5 (cg-RX-API-DMAC7.html)
JP2017193592A5 (cg-RX-API-DMAC7.html)
JP6662846B2 (ja) 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2020526549A5 (cg-RX-API-DMAC7.html)
JP7362600B2 (ja) Rip1キナーゼ阻害剤として使用するための二環式化合物
JP2009510043A5 (cg-RX-API-DMAC7.html)
CN105530932A (zh) 作为bik抑制剂的伯甲酰胺
US20160045505A1 (en) Compounds and compositions for the treatment of parasitic diseases
US20240300974A1 (en) Bicyclic ketone compounds and methods of use thereof
JP6661605B2 (ja) 6,7−ジヒドロピラゾロ[1,5−a]ピラジン−4(5H)−オン化合物およびMGLUR2受容体の負のアロステリック調節因子としてのそれらの使用
US20160324833A1 (en) Inhibitors of the renal outer medullary potassium channel
JP2020520925A5 (cg-RX-API-DMAC7.html)